Index

acetylcholinesterase inhibitor 245
acrylamide 127, 128
adenosine 53, 245-247, 250
adenosine kinase inhibitor
  (treating diabetic neuropathy) 141
adjuvant 38
α2-adrenergic agonist 245
α2-adrenergic antagonist 246
α1-adrenergic receptor
  (treating diabetic neuropathy) 141
α2-adrenoceptor agonist
  (treating diabetic neuropathy) 141
adrenoceptors, sympathetic-afferent coupling
  162
Aβ afferent fiber 177, 178, 192, 193
Aβ afferent fiber 23, 177, 178
afferent fiber, cutaneous 10, 12
afferent fiber, muscle 10-12
alcohol neuropathy 131
aldose reductase, in diabetes 136
aldose reductase inhibitor 137
alldynia 57, 110, 135, 136, 141, 142, 176,
  177, 181, 188, 190, 191, 211, 217, 221
alldynia, definition 177
alldynia, gabapentin 221
alldynia, in diabetes 135
alpha2-delta protein 220
amino acid, plasticity after nerve lesions 97
amitriptyline (treating diabetic neuropathy) 141
analgesic target 80
anticonvulsant drugs 211-214
anticonvulsant drugs, clinical studies 214
anticonvulsant drugs, mechanisms 214
anticonvulsant drugs, structures 211
anti-ganglioside GD2 antibody 130
AP5 (treating diabetic neuropathy) 141
axon tips, ongoing activity 11
axonotomy 9, 11, 29, 109
baclofen (treating diabetic neuropathy) 141
BDNF (treating diabetic neuropathy) 141
behavioral testing 110
bFGF 57
biogenic amines, plasticity after nerve lesions 98
bradykinin 7, 54
brain-derived neurothrophic factor (BDNF)
  52, 57, 141
Ca2+ channel blocker 82
calcitonin gene related peptide (CGRP)
  52, 55, 220
calcium channel antagonist, effect on 234
cannabinoid receptor agonist 83
carbamazepine 213
carbamazepine, painful diabetic neuropathy 213
carbamazepine, postherpetic neuralgia 213
carbamazepine, trigeminal neuralgia 213
carboplatin 129
carrageenan 38
catecholamine 8, 10
causalgia 153
central sensitization 117, 201
C-fiber 43, 54, 177, 178, 193
chemosensitivity, ectopic 7
Index

cholecystokinin (CCK) 55
chronic constriction injury (CCI) 34, 51, 109
ciliary neurotrophic factor (CNTF) 58, 141
cisplatin 128, 129
clonidine 141, 142, 246-250
CNTF (treating diabetic neuropathy) 141
cold allodynia 110
cold allodynia, effect of gabapentin 217
cold hyperalgesia 185
complex regional pain syndromes (CRPS) 154-156
CRPS, autonomic abnormality 155
CRPS type I (reflex sympathetic dystrophy) 154, 155
CRPS type II (causalgia) 155
cutaneous afferents 10, 12
cytokines 67
dexmedetomidine 248
dextromethorphan 217
diabetic neuropathy 132, 141, 142
dolorimeter 191
dorsal horn 100
dorsal rhizotomy 120
dorsal root ganglion (DRG) 23
DRG neurons, ongoing activity 12
dysesthesia 181
ectopic discharge 115
ectopic firing 218
ectopic spontaneous activity 52
electrogenesis 28
eンドセリン A (treating diabetic neuropathy) 141
felbamate 215
formalin (treating diabetic neuropathy) 141
formalin test, in diabetes 135
fos, plasticity after nerve lesions 93
GABA, release of 220
GABA transporter 216
gabapentin 81, 141, 142, 217
gabapentin, painful diabetic neuropathy 217
gabapentin, post-herpetic neuralgia 217
galanin (GAL) 55
ganglioside (treating diabetic neuropathy) 141
glial-derived growth factor GDNF 43, 52
 glutamate 201, 202, 219, 220
 glutamate receptor 201, 202
 glutamate, release of 219, 220
 guanethidine 153, 157
 heat hyperalgesia 110
 heavy metal 128
 hexocarbon 127
 hyperalgesia 110, 135, 136, 141, 176, 177, 185, 191, 211
 hyperalgesia, gabapentin 221
 hyperesthesia 181
 hyperexcitability 24, 28
 hyperhidrosis 183
 hyperpathia 181
 hypoalgesia 135, 136, 138, 181
 hypoesthesia 190

IB4 43
immunoreactivity, sodium channel 38
inflammatory component of CRPS I 155
interleukin-1β 70
interleukin-6 (IL-6) 57, 70
intravenous regional sympatholysis 153
ischemic neuropathy 176
lamotrigine 141, 215
leukemia inhibitory factor (LIF) 58
lidocaine 141, 142, 213
local anesthetic drugs 213
macrophage 69
mechanical allodynia 57, 110
mechanical hyperalgesia, in diabetes 135, 136, 141
mechanical threshold 110
mechanosensitivity, ectopic 4
memantine 217
mexiletine 141, 142, 213
MK-801 (treating diabetic neuropathy) 141
mononeuropathy 176
morphine (treating diabetic neuropathy) 141
muscarinic receptor 246, 250
muscle afferents 10-12

Na6 24
NaN 24
NBQX (treating diabetic neuropathy) 141
neostigmine 246
nerve growth factor (NGF) 41, 51
nerve injury model 89
neuritis 67
neuro-inflammation 67
neuropathic pain model 110
neuropathy 132, 141, 142, 176
neuropeptide, in diabetes 138
neuropeptide tyrosine (NPY) 55
neurotrophic factor, in diabetes 138
neurotrophin-3 (NT-3) 52
NGF (treating diabetic neuropathy) 140
nitric oxide (NO) 54
NK-1 receptor, antagonists 141
NMDA glutamate antagonists 217
nNOS, in diabetes 138
nociception 239
nociceptive processing 234
N type calcium channel antagonist SNX-239
(treating diabetic neuropathy) 141

opiate (treating diabetic neuropathy) 142
organophosphate 127
oscillation, of membrane potential 13

P2X3 53
paclitaxel 128, 130

paresthesia 181
partial sciatric nerve ligation model 115
peptide, plasticity after nerve lesions 96
persistent sodium current 25
phantom limb pain 153
phenytoin 128, 213, 214
phenytoin, diabetic neuropathy 214
pinprick hyperalgesia 191
pituitary adenylate cyclase activating peptide (PACAP) 55
platinum 128, 129
PN1 24
PN3 219
polyneuropathy 176
polyol pathway 136
post herpetic neuralgia 176, 182
post-traumatic neuralgia 153, 156
potassium channel, voltage-gated 216
pregabalin, painful diabetic neuropathy 218
pregabalin, post-herpetic neuralgia 218
prosaposin (treating diabetic neuropathy) 141
protein kinase C, gamma isoform 53
pyridoxine 132
pyroxidine (vitamine B6) 128

Quantitative Sensory Testing (QST) 188
quantitative sudomotor axon reflex test (QSART) 193

rapidly-repriming sodium current 29
receptors, plasticity after nerve lesions 98
reflex sympathetic dystrophy (RSD) 153
repriming kinetics 28
retigabine 216

sciatic nerve transection 51
segmental spinal nerve ligation model 114
sensitization 7, 12, 117, 201
serotonin (treating diabetic neuropathy) 141
SMP, human experimental studies 163
SNS 24, 27, 138, 219
SNS-null 27
Index

SNS sodium channel, in diabetes 138
α-III sodium channel 52
sodium channel
   23, 24, 29, 38, 52, 81, 138, 215, 218, 219
sodium channel blocker 81
sodium channel, immunoreactivity 38
sodium channel, PN3 219
sodium channel, SNS 138, 219
sodium channel, sustained currents 219
sodium channel, TTX-insensitive 52
sodium channel, TTX-sensitive 52
sodium channel, voltage sensitive 218
sodium current 24, 29
somatostatin (SOM) 55
SP 52, 55, 220
spinal sensory processing, in diabetes 138
sprouting, mechanoreceptors 54
sprouting, myelinated fibers 89
sprouting, unmyelinated fibers 92
substance P (SP) 52, 55, 220
sympathetic blockade, treatment of CRPS 156
sympathetic ganglia 194
sympathetic ganglion block 153
sympathetically maintained pain (SMP) 112, 157
tactile allodynia in diabetes 136, 141, 142
tail flick test, in diabetes 134, 136
tetrodotoxin (TTX) 24, 219
thalidomide 128, 131
thermal hyperalgesia, in diabetes 136
thermal hypoalgesia, in diabetes 135, 136, 138
thermosensitivity, etopic 5
tiagabine 216
tocainide 213
topiramate, painful diabetic neuropathy 216
transport, anterograde axoplasmic 8
tricyclic antidepressant (treating diabetic neuropathy) 141, 142
tricyclic drug, sodium channel blocker 215
trigeminal neuralgia 176, 213
TTX-resistant sodium current 24
TTX-sensitive sodium current 24
tumor necrosis factor-α (TNF) 70, 131
TX14(A) (treating diabetic neuropathy) 141
type III sodium channel 28
valproic acid 215
vasoactive intestinal peptide (VIP) 55
vigabatrin 220
vinblastine 129
vincristine 129
vinka alkaloids 128, 129
voltage-dependence 23, 25
voltage-dependent calcium channel (VDCC) 233
voltage-dependent calcium channel (VDCC) antagonist 239
von Frey filament 110
VR1 53
VRL-1 53
Wallerian degeneration 70
The PIR-Series
Progress in Inflammation Research

Homepage: http://www.birkhauser.ch

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:
T Cells in Arthritis, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Inducible Enzymes in the Inflammatory Response, D.A. Willoughby, A. Tomlinson (Editors), 1999
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999
Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs, K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000
High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000
Immunology and Drug Therapy of Atopic Skin Diseases, C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000
Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000
Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities, L.G. Letts, D.W. Morgan (Editors), 2000
Cellular Mechanisms in Airways Inflammation, C. Page, K. Banner, D. Spina (Editors), 2000
Inflammatory and Infectious Basis of Atherosclerosis, J.L. Mehta (Editor), 2001
Muscarinic Receptors in Airways Diseases, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001
TGF-β and Related Cytokines in Inflammation, S.N. Breit, S. Wahl (Editors), 2001
Nitric Oxide and Inflammation, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001
Neuroinflammatory Mechanisms in Alzheimer's Disease. Basic and Clinical Research, J. Rogers (Editor), 2001
Disease-modifying Therapy in Vasculitides, C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001
Inflammation and Stroke, G.Z. Feuerstein (Editor), 2001
NMDA Antagonists as Potential Analgesic Drugs, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002